US 7,566,701 B2
	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
John L. Diener, Cambridge, Mass. (US); H. A. Daniel Lagassé, Somerville, Mass. (US); and Claude Benedict, Cambridge, Mass. (US)
Assigned to Archemix Corp., Cambridge, Mass. (US)
Filed on Sep. 07, 2005, as Appl. No. 11/222,346.
Claims priority of provisional application 60/690231, filed on Jun. 13, 2005.
Claims priority of provisional application 60/678427, filed on May 06, 2005.
Claims priority of provisional application 60/661950, filed on Mar. 11, 2005.
Claims priority of provisional application 60/608047, filed on Sep. 07, 2004.
Prior Publication US 2006/0183702 A1, Aug. 17, 2006
Int. Cl. A01N 43/04 (2006.01); C12Q 1/68 (2006.01); C12P 19/34 (2006.01); C07H 21/02 (2006.01)

U.S. Cl. 514—44  [435/6; 435/91.1; 536/23.1]

19 Claims

1. An aptamer that binds to a von Willebrand Factor target, wherein the aptamer modulates von Willebrand Factor-mediated platelet adhesion, activation and/or aggregation and the aptamer is PEG20K-NH2-mGmCmGmUdGdCdAmGmUmGmCmCmUmUmCmGmGmCdCmG-s-TmGdCdGdGTmGmCdCmUdCdCmGmUdCmAmCmGmC-3T (SEQ ID No. 291) (ARC1779), where “NH2” is a 5′-hexylamine linker phosphoramidite, “3T” is an inverted deoxythymidine, “T” is a dT, “s” is a phosphorothioate backbone modification, “mN” is a 2′-O Methyl containing residue, “PEG” is a polyethylene glycol and “dN” is a deoxy residue, and wherein the aptamer comprises a KD for von Willebrand Factor of less than 100 nM.